Compare Gilead Sciences, Inc. (GILD) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tidewater Inc — how do they compare? Gilead Sciences, Inc. trades at $135.75 (market cap $168.35B), while Tidewater Inc trades at $91.58 (market cap $4.54B). The key difference: Gilead Sciences, Inc. is far larger — about 37.1× Tidewater Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| GILD | TDW | |
|---|---|---|
Market Cap | $168.35B | $4.54B |
Sector | Health | Utilities |
52-Week High | $155.80 | $91.20 |
52-Week Low | $110.56 | $47.29 |
Enterprise Value | $191.42B | $4.58B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Tidewater (TDW) trades at $91.86, up 2.49% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 earnings of $0.43 per share, beating estimates (Zacks, August 3, 2026), though it missed expectations in prior quarters. Revenue for the quarter was $342.3 million, with net income margins around 18%. Analyst sentiment is mixed, with 26.92% recommending Buy and 57.7% Hold.
Outlook: Strong day rates and utilization support revenue growth, but earnings misses and Middle East operational costs pose risks. The stock's valuation (P/E 18.5) is reasonable, but investors face volatility from oil market exposure and execution challenges. Upside depends on sustained operational improvements and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
